Research

Sean C. Bendall, PhD

Assistant Professor, Pathology, Stanford University

Postdoctoral Fellowship, Stanford University
Ph.D., University of Western Ontario
B.Sc., University of Victoria

bJe=nWd[aUl)l? (AMT- =sQt}a4nAfKo<r_dv.^endOuG

Our goal is to understand the mechanisms regulating the development of human systems (both embryonic and adult). In particular, we are interested in clarifying the roles of both protein coding genes as well as pathobiology (disease state or pathogen) known to be uniquely human – therefore, not analogously studied in model organisms. Drawing on both pluripotent stem cell biology, hematopoiesis, and immunology, combined with novel high-content single-cell analysis (CyTOF Mass Cytometry) and imaging (MIBI Multiplexed Ion Beam Imaging) we are creating templates of 'normal' human cellular behavior. Using these we can decipher the roles of protein regulators on cellular specification as well as the influence of human-specific pathobiology on system remodeling at the single cell level. This work will enable a better understanding of how disease corrupts this process. Ultimately, our objective will be to use such approaches to not only reveal how novel regulators function in the context of complex cellular systems, but also enable the mechanistic characterization of human pathobiology in primary human tissues. In doing so we will understand how changes in related physiological or pathological systems can be more readily recognized and controlled.

In addition to the lab's work on human hematopoiesis and pluripotent stem cell specification we are seeking collaborative partnerships surrounding problems in human immunology as well as in regenerative medicine, including efforts to exploit next generation single-cell analysis and new computational methods to create systems level models of these processes so that they may be better understood and directed.

Felix J. Hartmann, PhD

Postdoctoral fellow, Pathology, Stanford University
EMBO Long-Term Fellow
SNF Early Postdoc Fellow
Novartis Foundation Fellow

Ph.D., University of Zurich/ETH Zurich, Zurich, Switzerland
M.Sc., University of Heidelberg, Heidelberg, Germany
B.Sc., University of Heidelberg, Heidelberg, Germany

h(a[r{t?m1aXndfl dA]Tk Ts;tua[n)fGozr#dp.9e:dmul

Dunja Mrdjen, PhD

Postdoctoral fellow, Pathology, Stanford University
Swiss National Science Foundation Early Postdoc Mobility Fellowship

PhD in Immunology from University of Zurich, Switzerland
MSc in Clinical Science & Immunology, University of Cape Town, South Africa
BSc (Hons) in Medical Biochemistry, University of Cape Town, South Africa
BSc in Molecular & Cell Biology, University of Cape Town, South Africa

m7r@d1jeeJnSdL iA[To ts6t)a0nRfVo]r~d$.5eId3u{

I am working together with the Montine Lab to build predictive models for Alzheimer’s disease progression from genetically and pathologically highly characterized cohorts of human brain autopsy samples using Multiplexed Ion Beam Imaging (MIBI) and by implementing deep-learning for image analysis of cellular and sub-cellular targets in the brain. Integrating multi-platform and cross-species antibody panels, I also aim to leverage MIBI and CyTOF mass cytometry across human and model organism tissue to unravel microglial granularity in neurodegenerative diseases.

John-Paul Oliveria, PhD

Postdoctoral Fellow, Pathology, Stanford University
Adjunct Faculty, Medicine, McMaster University
Canadian Institute of Health Research (CIHR) Fellow

B.Sc., Biology, Specialized in Genetics, McMaster University
Ph.D., Medical Sciences, Specialized in Physiology and Pharmacology, McMaster University

o`ljiSvSe0r/i\aD )AET& 9sgtGa%n\f>oWr@dJ.ze(dKu<

Currently working on unraveling the mechanisms of Alzheimer's disease progression and resilience utilizing mass cytometry (CyTOF) and high-dimensional imaging (multiplexed ion beam imaging - MIBI-TOF).

Previously worked on evaluating the role of immune cells in allergic pathogenesis (IgE+ B cells, regulatory B cells or Bregs, basophils, type 2 innate lymphoid cells, eosinophils).

Nora Vivanco Gonzalez

PhD Candidate, Immunology, Stanford University
Blavatnik Family Fellowship

B.Sc., The University of Chicago

n6vZiHv2aknCc;o\ =A9T) "s0t8aPn`fKoarrdN.7e9d`ue

I use single-cell mass cytometry to study the extensive immunological adaptations of the maternal immune system during pregnancy using a mouse model.

Ariel Calderon

PhD Candidate, Immunology, Stanford University
GRFP Fellow, National Science Foundation
DARE Fellow, Stanford University

B.A., Biology, Hunter College at The City University of New York

aac\aBl3d_eMr7 VAtTt 9sitSaTnVf`o\r0dW.?ebdEu!

My project focuses on the deep phenotypic characterization of human NK cell development using CyTOF to classify human hematopoietic precursor cells through both surface markers, transcriptional markers and regulatory enzymes. My other interests lie in normal vs aberrant hematopoiesis and high dimensional data analysis.

David Glass

PhD Candidate, Computational and Systems Immunology, Stanford University
Bio-X Stanford Interdisciplinary Graduate Fellowship

B.Sc., University of Texas at Austin
B.Mus., Texas State University

dwr{g2lDaqs{s0 XA\Tq -sPt~aqnQfuomrkd*.Meddau'

My research aims to comprehensively characterize B cells in health and disease through the application of multi-omic single cell technologies. I am also developing new computational methods to analyze single cell datasets with applications in hematopoietic cancer diagnostics as well as basic research.

Geoff Ivison

PhD Candidate, Computational and Systems Immunology, Stanford University

B.A., Hampshire College

gRiMvGiss=oknc +A|TM oszt'a\nmfpoZr0dO.\e8d\u#

I am interested in understanding the mechanisms Natural Killer (NK) cells use to integrate the signals received by their panoply of activating and inhibitory receptors, as well as how and why different NK cell populations respond differently to the same stimuli. To address these questions, I am using CyTOF to look at NK cell phosphosignaling in response to a variety of stimuli.

YeEun Kim

PhD Candidate, Computational Systems Immunology, Stanford University
Baker International Fellowship
Co-advised by William Greenleaf

B.S., Seoul National University

yke\e[utn5k`iFmH $AvT0 ksVtAaVnwfho0r=d^.,eKd@ud

I study the lymphoid lineage specification in human hematopoiesis, especially T cell lineage specification in human bone marrow. I am interested in how epigenetic landscapes of the early hematopoietic progenitors control their specification and development.

Bryan Cannon

PhD Candidate, Computational and Systems Immunology, Stanford University

M.S. Molecular & Integrative Physiology, University of Michigan
B.S. Neuroscience, University of Michigan

b(rhyRjUc" "ATT' qs&tGa.nAfeo8rTdA.seGd|u?

Developing computational tools to interrogate high-dimensional protein multiplexing of human neuroimmunity.

Albert G. Tsai, MD, PhD

Former Postdoctoral Fellow, Bendall Laboratory
Assistant Professor, Pathology, Stanford University
Former Fellow, Damon Runyon Cancer Research Foundation

Diplomate, Hematopathology, American Board of Pathology
Diplomate, Anatomic and Clinical Pathology, American Board of Pathology
Fellowship, Hematopathology, Stanford University
Residency, Anatomic and Clinical Pathology, Stanford University
M.D., University of Southern California
Ph.D., Biochemistry, University of Southern California
B.S., Biochemistry, University of California, Los Angeles

a(gkt\ *AGT_ 0sGtpa3nLfpoTr1d'.;e:dQu-

My current research focus is in diagnostic uses and implementation of mass immunophenotyping (mass cytometry and multiplexed ion beam imaging), particularly for blood tumors such as lymphomas and leukemias. This includes biomarker development, protocol optimization, quality control, and reducing costs using computational analysis with potential automation through artificial intelligence/machine learning. Combining diagnostic practice with knowledge of clinical laboratory testing, access to primary patient samples, and postdoctoral work in mass immunophenotyping, I seek to advance the routine diagnosis of hematopoietic diseases using these emerging technologies.